Juvenile Dermatomyositis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Report Overview

The Global Juvenile Dermatomyositis Treatment Market reached US$ 71.15 million in 2023 and is expected to reach US$ 101.93 million by 2031, growing at a CAGR of 4.6% during the forecast period 2024-2031. 

Juvenile dermatomyositis is a rare autoimmune inflammatory condition in children affecting primarily skin and skeletal muscles. The condition is chronic and the frequent symptoms are muscle weakness, myalgia, skin lesions, pruritis, fever, dysphagia, and respiratory and GI symptoms. The condition is rare and accounts for nearly 4,000 prevalent cases in the U.S.

There is no specific treatment available to cure the condition, however, certain therapeutic options such as corticosteroids, immunosuppressants, and biologic drugs are available which prevent the disease progression and aid the patients to live healthy and longer lives.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Rising product development activities by market players

Juvenile dermatomyositis is a rare condition affecting children below 18 years of age. There is no specific treatment option currently available for JDM, and the existing therapies focus on alleviating the symptoms and preventing the disease progression. There are several product development activities, which if successful may provide broad-spectrum treatment options to the patients. These novel products may provide better therapeutic outcomes and improve the overall treatment rate-propelling the market positively in the forecast period.

For instance, biological therapies are currently revolutionizing the rare disease therapeutics market. For the treatment of juvenile dermatomyositis, Rituximab, abatacept, and infliximab were proven to be efficacious in treating patients with severe skin involvement, calcinosis, and resistant diseases. These biological therapies are currently a promising area for patients with severe symptoms.

Moreover, Baricitinib a janus kinase (JAK) inhibitor is currently under phase 2 clinical trials for the treatment of new-onset juvenile dermatomyositis. The study is anticipated to be finished by the end of 2026. This MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with corticosteroids in new-onset patients with juvenile dermatomyositis (JDM).

Additionally, in September 2024, the U.S. Food and Drug Administration (FDA) granted a rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). Descartes-08 developed by Cartesian Therapeutics, Inc. is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product currently ready for phase 2 basket study (multiple indications) for neurology and rheumatology autoimmune indications, including JDM.

Restraints

The market for juvenile dermatomyositis treatments is restrained by several factors such as side effects associated with the use of corticosteroids, and the rarity of the condition-limited patient population available for product development activities such as clinical trials.  

Market Segment Analysis

The global juvenile dermatomyositis treatment market is segmented based on treatment type, route of administration, patient type, distribution channel, and region.

Corticosteroids in the treatment type segment accounted for approximately 65.3% of the global juvenile dermatomyositis treatment market share.

Corticosteroids, especially prednisone are most widely used as first-line agents for treating juvenile dermatomyositis. For juvenile patients who are initially diagnosed with dermatomyositis, oral prednisone is given at higher doses for a longer duration of ~4 months, followed by other therapies such as methotrexate, cyclosporine, or other immunosuppressants with or without prednisone.

The main goal of treatment is to eliminate inflammation, restore muscle function, and further prevent the disability. According to the American College of Rheumatology, high-dose oral or intravenous corticosteroids are chosen as first-line agents for the condition. According to the Arthritis Foundation of America, corticosteroids are often used as a first-line therapy for juvenile dermatomyositis, due to their powerful anti-inflammatory effects and fast-acting capability.

Market Geographical Share

North America dominates the global juvenile dermatomyositis treatment market with a share of XX% in 2023, and growing at a CAGR of 43.5% in the forecast period

North America dominates the global juvenile dermatomyositis treatment market due to its advanced healthcare infrastructure and facilities, easy accessibility to a variety of treatments, availability of branded drugs offered by global pharmaceutical industry leaders, and increasing prevalence, etc.

For instance, in August 2024, an article published in MDPI journals on juvenile idiopathic inflammatory myopathies (JIIM) stated that juvenile dermatomyositis is the most common form of JIIM in the U.S., accounting for more than 80% of cases. The annual incidence of juvenile dermatomyositis is estimated to be between 1.9 to 4.1 per million children in the U.S. As per dataM estimates, the annual incidence cases are approximately 230-240 cases in the U.S.

The region is at the forefront of developing novel therapies for JDM. With the favorable regulatory policies, and the greater demand for advanced care, innovator companies focus on developing and launching their product first in this region. As a result, the patient population gets advanced access to these novel therapies. For instance, on September 9, 2024, the U.S. FDA provided a rare pediatric designation for Descartes-08 to treat juvenile dermatomyositis. The drug, if completes clinical studies, may get launched first in the U.S. market.

Hence, considering these factors, along with the epidemiological data and sales figures by market leaders, North America is designated as a dominant region in the global market.

Market Segmentation

By Treatment Type

• Corticosteroids
• Immunosuppressants
  • Methotrexate
  • Cyclosporine
  • Mycophenolate Mofetil
  • Others
• Intravenous Immunoglobulin (IVIG)
• Hydroxychloroquine
• Targeted Therapies
  • Infliximab
  • Rituximab
  • Abatacept
  • Others
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Patient Type

• Male
• Female

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major players in the juvenile dermatomyositis treatment market include Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Octapharma USA, Inc., AbbVie Inc., Horizon Therapeutics plc, Viatris Inc. and Sandoz AG among others.

Why Purchase the Report?

• To visualize the global juvenile dermatomyositis treatment market segmentation based on treatment type, route of administration, patient type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of juvenile dermatomyositis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global juvenile dermatomyositis treatment market report would provide approximately 70 tables, 64 figures, and 212 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies